Xeljanz, manufactured by the pharmaceutical company Pfizer, treats certain severe, chronic, and progressive inflammatory conditions. It was approved by the Food and Drug Administration (FDA) in 2012 to treat rheumatoid arthritis (RA), psoriatic arthritis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis.
However, in 2019, the FDA issued a drug safety communication after interim results from a safety trial found an increased risk of serious heart-related problems and cancer associated with Xeljanz. The safety trial results showed an increased risk of blood clots and death associated with the 10 mg dose. Accordingly, the FDA approved a Boxed Warning to the Xeljanz prescribing information.
Therefore, if you or a loved one experienced heart-related problems or other injuries after taking Xeljanz, you may be entitled to compensation by filing a claim against the manufacturer of Xeljanz. Please complete the form below for a free consultation if you believe this applies to you.